Advice
Following a full submission.
Ibandronic acid is accepted for use within NHS Scotland for the prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.
It reduces the rate of skeletal events consisting of a composite of vertebral fractures, pathological non-vertebral fractures and the need for radiotherapy or surgery to deal with bone complications. It can be given both by the oral or intravenous route.
Download detailed advice27KB (PDF)
Medicine details
- Medicine name:
- Ibandronic acid (Bondronat®)
- SMC ID:
- 123/04
- Indication:
- Metastatic bone disease
- Pharmaceutical company
- Roche
- BNF chapter
- Endocrine system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 11 October 2004